These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6271814)

  • 1. Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications.
    Levitt M; Wilson A; Bowman D; Kemel S; Krepart G; Marks V; Schipper H; Thomson G; Weinerman B; Weinerman R
    J Clin Pharmacol; 1981; 21(S1):103S-109S. PubMed ID: 6271814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine.
    Orr LE; McKernan JF
    J Clin Pharmacol; 1981; 21(S1):76S-80S. PubMed ID: 6271846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy.
    Lucas VS; Laszlo J
    JAMA; 1980 Mar; 243(12):1241-3. PubMed ID: 6244418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy.
    Chang AE; Shiling DJ; Stillman RC; Goldberg NH; Seipp CA; Barofsky I; Rosenberg SA
    Cancer; 1981 Apr; 47(7):1746-51. PubMed ID: 6261926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.
    Orr LE; McKernan JF; Bloome B
    Arch Intern Med; 1980 Nov; 140(11):1431-3. PubMed ID: 6254456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
    Frytak S; Moertel CG; O'Fallon JR; Rubin J; Creagan ET; O'Connell MJ; Schutt AJ; Schwartau NW
    Ann Intern Med; 1979 Dec; 91(6):825-30. PubMed ID: 517882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. delta 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study.
    Sweet DL; Miller NJ; Weddington W; Senay E; Sushelsky L
    J Clin Pharmacol; 1981; 21(S1):70S-75S. PubMed ID: 6271845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
    Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
    Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. delta 9-tetrahydrocannabinol in clinical oncology.
    Poster DS; Penta JS; Bruno S; Macdonald JS
    JAMA; 1981 May 22-29; 245(20):2047-51. PubMed ID: 6262541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine.
    Ungerleider JT; Andrysiak T; Fairbanks L; Goodnight J; Sarna G; Jamison K
    Cancer; 1982 Aug; 50(4):636-45. PubMed ID: 6284334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.
    McCabe M; Smith FP; Macdonald JS; Woolley PV; Goldberg D; Schein PS
    Invest New Drugs; 1988 Sep; 6(3):243-6. PubMed ID: 2847994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stress inoculation training in the control of THC toxicities.
    Roffman RA
    Int J Addict; 1986 Aug; 21(8):883-96. PubMed ID: 3021638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent clinical experience with dronabinol.
    Plasse TF; Gorter RW; Krasnow SH; Lane M; Shepard KV; Wadleigh RG
    Pharmacol Biochem Behav; 1991 Nov; 40(3):695-700. PubMed ID: 1666930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.
    Sallan SE; Cronin C; Zelen M; Zinberg NE
    N Engl J Med; 1980 Jan; 302(3):135-8. PubMed ID: 6985702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative trial of the antiemetic effects of THC and haloperidol.
    Neidhart JA; Gagen MM; Wilson HE; Young DC
    J Clin Pharmacol; 1981; 21(S1):38S-42S. PubMed ID: 6271838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of cannabinoids and their antiemetic effectiveness.
    Vincent BJ; McQuiston DJ; Einhorn LH; Nagy CM; Brames MJ
    Drugs; 1983 Feb; 25 Suppl 1():52-62. PubMed ID: 6301800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation.
    Chang AE; Shiling DJ; Stillman RC; Goldberg NH; Seipp CA; Barofsky I; Simon RM; Rosenberg SA
    Ann Intern Med; 1979 Dec; 91(6):819-24. PubMed ID: 293141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.
    Einhorn LH; Nagy C; Furnas B; Williams SD
    J Clin Pharmacol; 1981; 21(S1):64S-69S. PubMed ID: 6271844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.
    Gilbert CJ; Ohly KV; Rosner G; Peters WP
    Cancer; 1995 Dec; 76(11):2330-7. PubMed ID: 8635039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.
    Sallan SE; Zinberg NE; Frei E
    N Engl J Med; 1975 Oct; 293(16):795-7. PubMed ID: 1099449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.